New inhibitors of glycogen phosphorylase as potential antidiabetic agents

L. Somsák, K. Czifrák, M. Tóth, É Bokor, E. D. Chrysina, K. M. Alexacou, J. M. Hayes, C. Tiraidis, E. Lazoura, D. D. Leonidas, S. E. Zographos, N. G. Oikonomakos

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

The protein glycogen phosphorylase has been linked to type 2 diabetes, indicating the importance of this target to human health. Hence, the search for potent and selective inhibitors of this enzyme, which may lead to antihyperglycaemic drugs, has received particular attention. Glycogen phosphorylase is a typical allosteric protein with five different ligand binding sites, thus offering multiple opportunities for modulation of enzyme activity. The present survey is focused on recent new molecules, potential inhibitors of the enzyme. The biological activity can be modified by these molecules through direct binding, allosteric effects or other structural changes. Progress in our understanding of the mechanism of action of these inhibitors has been made by the determination of high-resolution enzyme inhibitor structures (both muscle and liver). The knowledge of the three-dimensional structures of protein-ligand complexes allows analysis of how the ligands interact with the target and has the potential to facilitate structure-based drug design. In this review, the synthesis, structure determination and computational studies of the most recent inhibitors of glycogen phosphorylase at the different binding sites are presented and analyzed.

Original languageEnglish
Pages (from-to)2933-2983
Number of pages51
JournalCurrent Medicinal Chemistry
Volume15
Issue number28
DOIs
Publication statusPublished - Dec 2008

Fingerprint

Glycogen Phosphorylase
Enzyme Inhibitors
Hypoglycemic Agents
Ligands
Binding Sites
Proteins
Molecules
Drug Design
Enzyme activity
Medical problems
Bioactivity
Pharmaceutical Preparations
Liver
Type 2 Diabetes Mellitus
Muscle
Modulation
Health
Muscles
Enzymes

Keywords

  • Antidiabetic agent
  • Glycogen phosphorylase
  • Inhibitor
  • Structure-based drug design
  • Type 2 diabetes

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

New inhibitors of glycogen phosphorylase as potential antidiabetic agents. / Somsák, L.; Czifrák, K.; Tóth, M.; Bokor, É; Chrysina, E. D.; Alexacou, K. M.; Hayes, J. M.; Tiraidis, C.; Lazoura, E.; Leonidas, D. D.; Zographos, S. E.; Oikonomakos, N. G.

In: Current Medicinal Chemistry, Vol. 15, No. 28, 12.2008, p. 2933-2983.

Research output: Contribution to journalArticle

Somsák, L, Czifrák, K, Tóth, M, Bokor, É, Chrysina, ED, Alexacou, KM, Hayes, JM, Tiraidis, C, Lazoura, E, Leonidas, DD, Zographos, SE & Oikonomakos, NG 2008, 'New inhibitors of glycogen phosphorylase as potential antidiabetic agents', Current Medicinal Chemistry, vol. 15, no. 28, pp. 2933-2983. https://doi.org/10.2174/092986708786848659
Somsák, L. ; Czifrák, K. ; Tóth, M. ; Bokor, É ; Chrysina, E. D. ; Alexacou, K. M. ; Hayes, J. M. ; Tiraidis, C. ; Lazoura, E. ; Leonidas, D. D. ; Zographos, S. E. ; Oikonomakos, N. G. / New inhibitors of glycogen phosphorylase as potential antidiabetic agents. In: Current Medicinal Chemistry. 2008 ; Vol. 15, No. 28. pp. 2933-2983.
@article{1d3a884f425d4e598acaf51d8dd3fac7,
title = "New inhibitors of glycogen phosphorylase as potential antidiabetic agents",
abstract = "The protein glycogen phosphorylase has been linked to type 2 diabetes, indicating the importance of this target to human health. Hence, the search for potent and selective inhibitors of this enzyme, which may lead to antihyperglycaemic drugs, has received particular attention. Glycogen phosphorylase is a typical allosteric protein with five different ligand binding sites, thus offering multiple opportunities for modulation of enzyme activity. The present survey is focused on recent new molecules, potential inhibitors of the enzyme. The biological activity can be modified by these molecules through direct binding, allosteric effects or other structural changes. Progress in our understanding of the mechanism of action of these inhibitors has been made by the determination of high-resolution enzyme inhibitor structures (both muscle and liver). The knowledge of the three-dimensional structures of protein-ligand complexes allows analysis of how the ligands interact with the target and has the potential to facilitate structure-based drug design. In this review, the synthesis, structure determination and computational studies of the most recent inhibitors of glycogen phosphorylase at the different binding sites are presented and analyzed.",
keywords = "Antidiabetic agent, Glycogen phosphorylase, Inhibitor, Structure-based drug design, Type 2 diabetes",
author = "L. Soms{\'a}k and K. Czifr{\'a}k and M. T{\'o}th and {\'E} Bokor and Chrysina, {E. D.} and Alexacou, {K. M.} and Hayes, {J. M.} and C. Tiraidis and E. Lazoura and Leonidas, {D. D.} and Zographos, {S. E.} and Oikonomakos, {N. G.}",
year = "2008",
month = "12",
doi = "10.2174/092986708786848659",
language = "English",
volume = "15",
pages = "2933--2983",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "28",

}

TY - JOUR

T1 - New inhibitors of glycogen phosphorylase as potential antidiabetic agents

AU - Somsák, L.

AU - Czifrák, K.

AU - Tóth, M.

AU - Bokor, É

AU - Chrysina, E. D.

AU - Alexacou, K. M.

AU - Hayes, J. M.

AU - Tiraidis, C.

AU - Lazoura, E.

AU - Leonidas, D. D.

AU - Zographos, S. E.

AU - Oikonomakos, N. G.

PY - 2008/12

Y1 - 2008/12

N2 - The protein glycogen phosphorylase has been linked to type 2 diabetes, indicating the importance of this target to human health. Hence, the search for potent and selective inhibitors of this enzyme, which may lead to antihyperglycaemic drugs, has received particular attention. Glycogen phosphorylase is a typical allosteric protein with five different ligand binding sites, thus offering multiple opportunities for modulation of enzyme activity. The present survey is focused on recent new molecules, potential inhibitors of the enzyme. The biological activity can be modified by these molecules through direct binding, allosteric effects or other structural changes. Progress in our understanding of the mechanism of action of these inhibitors has been made by the determination of high-resolution enzyme inhibitor structures (both muscle and liver). The knowledge of the three-dimensional structures of protein-ligand complexes allows analysis of how the ligands interact with the target and has the potential to facilitate structure-based drug design. In this review, the synthesis, structure determination and computational studies of the most recent inhibitors of glycogen phosphorylase at the different binding sites are presented and analyzed.

AB - The protein glycogen phosphorylase has been linked to type 2 diabetes, indicating the importance of this target to human health. Hence, the search for potent and selective inhibitors of this enzyme, which may lead to antihyperglycaemic drugs, has received particular attention. Glycogen phosphorylase is a typical allosteric protein with five different ligand binding sites, thus offering multiple opportunities for modulation of enzyme activity. The present survey is focused on recent new molecules, potential inhibitors of the enzyme. The biological activity can be modified by these molecules through direct binding, allosteric effects or other structural changes. Progress in our understanding of the mechanism of action of these inhibitors has been made by the determination of high-resolution enzyme inhibitor structures (both muscle and liver). The knowledge of the three-dimensional structures of protein-ligand complexes allows analysis of how the ligands interact with the target and has the potential to facilitate structure-based drug design. In this review, the synthesis, structure determination and computational studies of the most recent inhibitors of glycogen phosphorylase at the different binding sites are presented and analyzed.

KW - Antidiabetic agent

KW - Glycogen phosphorylase

KW - Inhibitor

KW - Structure-based drug design

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=58149402805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149402805&partnerID=8YFLogxK

U2 - 10.2174/092986708786848659

DO - 10.2174/092986708786848659

M3 - Article

C2 - 19075645

AN - SCOPUS:58149402805

VL - 15

SP - 2933

EP - 2983

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 28

ER -